Home >> Law >> Food & Beverage >>

Genextra S.p.a. - Product Pipeline Review - 2015

Published: May-2015 | Format: PDF | Global Markets Direct | Number of pages: 21 | Code: MRS - 19822

Genextra S.p.a. - Product Pipeline Review - 2015


Global Markets Direct’s, ‘Genextra S.p.a. - Product Pipeline Review - 2015’, provides an overview of the Genextra S.p.a.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genextra S.p.a.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Genextra S.p.a. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genextra S.p.a.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Genextra S.p.a.’s pipeline products

Reasons to buy

- Evaluate Genextra S.p.a.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genextra S.p.a. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genextra S.p.a.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genextra S.p.a. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genextra S.p.a.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genextra S.p.a. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Genextra S.p.a. Snapshot 4
Genextra S.p.a. Overview 4
Key Information 4
Key Facts 4
Genextra S.p.a. - Research and Development Overview 5
Key Therapeutic Areas 5
Genextra S.p.a. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Genextra S.p.a. - Pipeline Products Glance 9
Genextra S.p.a. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Genextra S.p.a. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Genextra S.p.a. - Drug Profiles 11
DAC-060 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Drugs to Inhibit HDAC for Oncology 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Small Molecules to inhibit HSP90 for Oncology 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Genextra S.p.a. - Pipeline Analysis 14
Genextra S.p.a. - Pipeline Products by Target 14
Genextra S.p.a. - Pipeline Products by Route of Administration 15
Genextra S.p.a. - Pipeline Products by Molecule Type 16
Genextra S.p.a. - Pipeline Products by Mechanism of Action 17
Genextra S.p.a. - Dormant Projects 18
Genextra S.p.a. - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 20
Disclaimer 21

List of Tables
Genextra S.p.a., Key Information 4
Genextra S.p.a., Key Facts 4
Genextra S.p.a. - Pipeline by Indication, 2015 6
Genextra S.p.a. - Pipeline by Stage of Development, 2015 7
Genextra S.p.a. - Monotherapy Products in Pipeline, 2015 8
Genextra S.p.a. - Phase II, 2015 9
Genextra S.p.a. - Preclinical, 2015 10
Genextra S.p.a. - Pipeline by Target, 2015 14
Genextra S.p.a. - Pipeline by Route of Administration, 2015 15
Genextra S.p.a. - Pipeline by Molecule Type, 2015 16
Genextra S.p.a. - Pipeline Products by Mechanism of Action, 2015 17
Genextra S.p.a. - Dormant Developmental Projects,2015 18
Genextra S.p.a., Subsidiaries 19

List of Figures
Genextra S.p.a. - Pipeline by Top 10 Indication, 2015 6
Genextra S.p.a. - Pipeline by Stage of Development, 2015 7
Genextra S.p.a. - Monotherapy Products in Pipeline, 2015 8
Genextra S.p.a. - Pipeline by Top 10 Target, 2015 14
Genextra S.p.a. - Pipeline by Top 10 Molecule Type, 2015 16
Genextra S.p.a. - Pipeline Products by Top 10 Mechanism of Action, 2015 17

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing